Portal de Periódicos da CAPES

Renal failure after treatment with ritonavir

1996; Elsevier BV; Volume: 348; Issue: 9028 Linguagem: Inglês

10.1016/s0140-6736(05)65125-2

1474-547X

Michel Duong, Catherine Sgro, Michelle Grappin, F. Biron, A. Boibieux,

HIV Research and Treatment

Ritonavir, an inhibitor of HIV protease, is used in the treatment of symptomatic HIV infection in combination with nucleoside analogues. 1 Cameron B, Heath-Chiozzi M, Kravei S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir (abstract). Third Conference on Retroviruses and Opportunistic Infections, IDSA, NIH and CDC, Jan 28-Feb 1, 1996, Washington, DC. Google Scholar Ritonavir's most common adverse events are gastrointestinal and neurological disturbances. Biological abnormalities are hypertriglyceridaemia and increase in transaminases. 1 Cameron B, Heath-Chiozzi M, Kravei S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir (abstract). Third Conference on Retroviruses and Opportunistic Infections, IDSA, NIH and CDC, Jan 28-Feb 1, 1996, Washington, DC. Google Scholar , 2 Markowitz M Saag M Powderly WG et al. A preliminary study of ritonavir, an inhibitor of HIV-protease, to treat HIV-1 infection. N Engl J Med. 1995; 333: 1534-1539 Crossref PubMed Scopus (464) Google Scholar , 3 Danner SA Carr A Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995; 333: 1528-1533 Crossref PubMed Scopus (526) Google Scholar Little is known about the effect of ritonavir on renal faction. We report development of renal insufficiency within 10–15 days of start of ritonavir in three patients with AIDS (table).